Amgen (AMGN) Stock Price
Amgen Price
Amgen (AMGN) Stock | ISIN US0311621009 | WKN 867900. The current Amgen stock price is 345.73 USD (2026). Revenue is 38.59 B USD. Net income is 12.37 B USD. The P/E ratio is 15.15. Market capitalization is 187.39 B USD. Amgen operates in the Health sector.
Amgen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Amgen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Amgen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Amgen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Amgen Price |
|---|
Amgen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Amgen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (USD)DIV. (USD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Amgen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Amgen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Amgen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Amgen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Amgen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Amgen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Amgen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Amgen business model & stock analysis
Amgen SWOT Analysis
Strengths
Amgen Inc. possesses several strengths that contribute to its success in the biotechnology industry. These strengths include:
- Strong research and development capabilities, allowing the company to innovate and develop cutting-edge biopharmaceutical products
- Diverse portfolio of products, enabling Amgen to cater to various therapeutic areas and target a wide range of diseases
- Global presence and established reputation, providing a competitive advantage and facilitating access to international markets
- Solid financial performance, with consistent revenue growth and strong profitability
- Robust intellectual property portfolio, safeguarding the company's innovations and providing a barrier to entry for competitors
Weaknesses
Despite its strengths, Amgen Inc. also faces certain weaknesses that may pose challenges to its growth and competitiveness:
- Dependency on a limited number of blockbuster drugs, making the company vulnerable to patent expiration and generic competition
- Reliance on external partnerships for some drug development programs, which may introduce uncertainties and potential conflicts of interest
- Higher production costs compared to traditional pharmaceutical companies due to the complexity of biologics manufacturing processes
- Occasional regulatory hurdles and legal disputes, leading to delays in product approvals and potential reputational damage
Opportunities
Amgen Inc. can capitalize on various opportunities in the biotechnology market to further enhance its position and drive growth:
- Increasing demand for biologics and personalized medicine, presenting a significant market potential for Amgen's specialized products
- Expanding into emerging markets, where there is a growing need for advanced healthcare solutions
- Investing in research and development to explore new therapeutic areas and expand the company's product pipeline
- Strategic acquisitions or collaborations to access complementary technologies or gain entry into new markets
Threats
Amgen Inc. must also navigate several threats that could negatively impact its operations and market position:
- Intense competition from other biotechnology companies and traditional pharmaceutical giants
- Potential price pressures and reimbursement challenges as payers seek to contain healthcare costs
- Increasingly stringent regulatory requirements and evolving regulations that may impact product development and commercialization
- Rapid technological advancements and potential disruption from biosimilars or other competitive innovations
Amgen Segments
Amgen Revenue by Segment (1/3)
3 Years
Max
Details
Amgen Revenue by Segment (2/3)
3 Years
Max
Details
Amgen Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Amgen Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Amgen Eulerpool Fair Value
Amgen historical P/E ratio, EBIT multiple, and P/S ratio
Amgen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Amgen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Amgen Dividend History
16 years of dividend payments · 7 consecutive increases
Amgen dividend history and estimates
Max
Details
Amgen dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Amgen Earnings Calls
Amgen Earnings Estimates
Amgen Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/30/2026 | 4.87USD | 8.75 BUSD | 2026 Q1 |
| 2/3/2026 | 4.81USD | 9.65 BUSD | 2025 Q4 |
| 2/2/2026 | 4.81USD | 9.64 BUSD | 2025 Q4 |
| 4/25/2024 | 4.45USD | 7.73 BUSD | 2024 Q1 |
| 1/29/2024 | 4.71USD | 8.29 BUSD | 2023 Q4 |
| 8/2/2023 | 4.81USD | 6.87 BUSD | 2023 Q2 |
| 4/25/2023 | 4.56USD | 6.57 BUSD | 2023 Q1 |
| 2/6/2023 | 4.16USD | 6.86 BUSD | 2022 Q4 |
| 11/3/2022 | 4.53USD | 6.66 BUSD | 2022 Q3 |
| 8/4/2022 | 4.48USD | 6.62 BUSD | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Amgen stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Amgen Executives and Management Board
Mr. Robert Bradway
(62)Chairman of the Board, President, Chief Executive Officer · since 2007
Dr. James Bradner
(53)Executive Vice President - Research and Development and Chief Scientific Officer
Mr. Murdo Gordon
(58)Executive Vice President - Global Commercial Operations
Dr. David Reese
(61)Executive Vice President, Chief Technology Officer
Mr. Peter Griffith
(66)Chief Financial Officer, Executive Vice President
Amgen Supply Chain
Frequently asked questions about Amgen
Amgen Inc is a leading biotechnology company with a strong business model focused on discovering, developing, and delivering innovative human therapeutics. The company operates through two main segments: Amgen's innovative medicines segment and its biosimilars segment. Amgen's innovative medicines segment focuses on the development and commercialization of innovative products in the areas of oncology, cardiovascular disease, inflammation, bone health, and neuroscience. The biosimilars segment aims to offer more affordable alternatives to existing biological therapies. With a commitment to research and development, Amgen Inc continually strives to address unmet medical needs and improve patients' lives.
Amgen stock
Amgen Peer Group
Amgen Ticker
Amgen FIGI
All fundamentals and in-depth analysis of Amgen
Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.